Blocking type 1 interferon for severe hidradenitis suppurativa
Part of Infections, Skin clinical trials.
This study tests a new treatment that blocks a protein called type 1 interferon, which may reduce inflammation and pain in severe hidradenitis suppurativa. It is for people who have not improved with standard treatments like antibiotics or biologic drugs.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 years or older
- You have hidradenitis suppurativa that is severe (Hurley stage II or III) and affects at least two body areas
- You have at least 3 abscesses or inflamed nodules and a high disease activity score (IHS4 ≥ 11)
- You take strong painkillers (opioids) for pain at a dose of at least 20 mg per day
- You have already tried certain antibiotics and biologic drugs (like adalimumab, infliximab, or secukinumab) for at least 3 months without success
- Your vaccinations for COVID-19 and flu are up to date, or you can get them before the study starts
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study looks at certain immune cells (called MAIT cells) in the skin of people with hidradenitis suppurativa, a painful skin condition. It will compare samples from people before they start a new biologic treatment, and may help doctors understand how these treatments work.
This study tests a new medicine given by injection (anti-IL-17A/F antibody) combined with a laser treatment (non-ablative dot laser) for people with mild to moderate hidradenitis suppurativa (also called HS). The goal is to see if the combination is safe and works better than current options, and might help reduce pain and flare-ups.
This study tests a drug called secukinumab (a type of biologic that targets inflammation) for people with moderate to severe hidradenitis suppurativa (HS). It may be an option if you have tried other treatments and they didn't work well.
This trial tests a new medication called CIT-013 for people with moderate to severe hidradenitis suppurativa (HS) who have not had enough relief from oral antibiotics. The goal is to see if this treatment can reduce painful bumps and abscesses.
This study tests whether botulinum toxin (Botox) injections can help treat hidradenitis suppurativa (HS), a skin condition with painful bumps. The goal is to see if blocking certain nerve signals can reduce HS flare-ups.
This trial tests a new medicine called SCT650C for people with moderate to severe hidradenitis suppurativa (HS). The goal is to see if it can reduce painful bumps and abscesses better than current treatments.
Hear when a new Hidradenitis Suppurativa (HS) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.